EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

(Alliance News) - GSK PLC on Monday said linerixibat has been accepted for review by the European Medicines Agency for the treatment of intense itching caused by a rare autoimmune liver disease.

Pruritus, or itching, is a common symptom of Primary Biliary Cholangitis (PBC). Learn more about its impact and the importance of raising awareness about this condition.

Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction to her laundry detergent. 'I was itching all the time,' recalls the 41-year ...

“If your itching is caused by a liver problem, there won’t be a skin rash or an insect bite,” the Liver Foundation says. The ...

Biliary tract cancer is a rare adenocarcinoma that occurs in a bile duct, often causing jaundice, pruritus and weight loss. The lesion may be papillary or flat and ulcerated.

Primary biliary cholangitis causes are not fully understood but may involve autoimmune responses. Common primary biliary cholangitis symptoms include fatigue and itching.